• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用决策辅助工具来改善癌症化疗患者与医生之间关于口服补充和替代医学(CAM)使用的知情决策和沟通:一项随机对照试验。

Use of decision aid to improve informed decision-making and communication with physicians on the use of oral complementary and alternative medicine (CAM) among cancer patients on chemotherapy treatment: a randomised controlled trial.

机构信息

Department of Haematology-Oncology, National University Cancer Institute, Singapore, 1E Lower Kent Ridge Road, Singapore, 119228, Singapore.

Department of Medicine, National University Hospital, Singapore, Singapore.

出版信息

Support Care Cancer. 2021 Jul;29(7):3689-3696. doi: 10.1007/s00520-020-05872-5. Epub 2020 Nov 14.

DOI:10.1007/s00520-020-05872-5
PMID:33188612
Abstract

PURPOSE

Complementary and alternative medicine (CAM) is often used by cancer patients and is concerning as concomitant oral CAM and chemotherapy use may result in adverse interactions and toxicities. We hypothesise that a decision aid (DA) may promote informed and rational use of oral CAM during chemotherapy, and increase patients' discussion with their oncologists on CAM use.

METHODS

We randomised 240 patients initiating chemotherapy to receive DA or none. Questionnaires were administered at randomisation (visit 1), 1 month (visit 2) and 3 months (visit 3). The primary endpoint was the decisional conflict score (DCS) for decision made on CAM use during chemotherapy. Secondary endpoints include patients' decision regret score (DRS) on CAM use, CAM uptake, discussion with oncologists on CAM usage, and difference in quality of life (QoL) score between CAM and non-CAM users at visit 3.

RESULTS

There was no difference in the mean DCS (mean difference 2.7 [95 CI - 2.9 to 8.3, p = 0.345]) and DRS (mean difference - 0.3 [95% CI - 6.3 to 5.8, p = 0.926]) between the two arms. There was a reduction in odds of CAM usage in the intervention arm compared to control arm (OR = 0.36, 95% CI 0.17 to 0.78, p = 0.009), but there was no difference in discussion with oncologists on CAM usage (OR = 0.46, 95% CI 0.07 to 3.01, p = 0.419), or in the QoL between CAM and non-CAM users.

CONCLUSION

Our DA did not reduce DCS among cancer patients on chemotherapy. DA that provides more evidence-based information on CAM, and non-judgemental discussion initiated by oncologists to discuss CAM, may improve its effectiveness.

摘要

目的

补充和替代医学(CAM)经常被癌症患者使用,令人担忧的是,同时使用口服 CAM 和化疗可能会导致不良反应和毒性。我们假设决策辅助工具(DA)可能会促进癌症患者在化疗期间明智而理性地使用口服 CAM,并增加患者与肿瘤医生讨论 CAM 使用的情况。

方法

我们将 240 名开始化疗的患者随机分为接受 DA 或不接受 DA 两组。在随机分组时(第 1 次就诊)、1 个月(第 2 次就诊)和 3 个月(第 3 次就诊)时进行问卷调查。主要终点是化疗期间 CAM 使用决策的决策冲突评分(DCS)。次要终点包括患者对 CAM 使用的决策后悔评分(DRS)、CAM 使用率、与肿瘤医生讨论 CAM 使用情况,以及第 3 次就诊时 CAM 和非 CAM 用户之间的生活质量(QoL)评分差异。

结果

两组之间的平均 DCS(平均差值 2.7 [95%CI-2.9 至 8.3,p = 0.345])和 DRS(平均差值-0.3 [95%CI-6.3 至 5.8,p = 0.926])均无差异。与对照组相比,干预组使用 CAM 的可能性降低(OR = 0.36,95%CI 0.17 至 0.78,p = 0.009),但与肿瘤医生讨论 CAM 使用情况的差异无统计学意义(OR = 0.46,95%CI 0.07 至 3.01,p = 0.419),CAM 和非 CAM 用户之间的 QoL 也无差异。

结论

我们的 DA 并未降低化疗癌症患者的 DCS。提供更多关于 CAM 的基于证据的信息,以及肿瘤医生发起的非评判性讨论来讨论 CAM,可能会提高其效果。

相似文献

1
Use of decision aid to improve informed decision-making and communication with physicians on the use of oral complementary and alternative medicine (CAM) among cancer patients on chemotherapy treatment: a randomised controlled trial.使用决策辅助工具来改善癌症化疗患者与医生之间关于口服补充和替代医学(CAM)使用的知情决策和沟通:一项随机对照试验。
Support Care Cancer. 2021 Jul;29(7):3689-3696. doi: 10.1007/s00520-020-05872-5. Epub 2020 Nov 14.
2
Randomized controlled trial on the effect of an online decision aid for young female cancer patients regarding fertility preservation.随机对照试验研究在线决策辅助工具对年轻女性癌症患者生育力保存的效果。
Hum Reprod. 2019 Sep 29;34(9):1726-1734. doi: 10.1093/humrep/dez136.
3
Development of an evidence-based decision aid on complementary and alternative medicine (CAM) and pain for parents of children with cancer.开发一种基于证据的关于补充和替代医学(CAM)与癌症儿童父母疼痛的决策辅助工具。
Support Care Cancer. 2020 May;28(5):2415-2429. doi: 10.1007/s00520-019-05058-8. Epub 2019 Sep 6.
4
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.参加I期试验的晚期癌症患者的补充和替代医学:一项关于预后、生活质量及决策偏好的研究。
J Clin Oncol. 2007 Feb 10;25(5):548-54. doi: 10.1200/JCO.2005.03.9800.
5
Complementary and alternative medicine among Singapore cancer patients.新加坡癌症患者中的补充和替代医学。
Ann Acad Med Singap. 2010 Feb;39(2):129-35.
6
Complementary and alternative medicine use, spending, and quality of life in early stage breast cancer.补充和替代医学的使用、支出与早期乳腺癌患者的生活质量。
Nurs Res. 2010 Jan-Feb;59(1):58-66. doi: 10.1097/NNR.0b013e3181c3bd26.
7
Communication and information needs about complementary and alternative medicine: a qualitative study of parents of children with cancer.补充和替代医学的沟通和信息需求:对癌症患儿父母的定性研究。
BMC Complement Med Ther. 2021 Mar 8;21(1):85. doi: 10.1186/s12906-021-03253-x.
8
Efficacy of open dialogue about complementary and alternative medicine compared with standard care in improving quality of life in patients undergoing conventional oncology treatment (CAMONCO 2): protocol for a randomised controlled trial.补充和替代医学开放对话与常规肿瘤治疗标准护理比较对改善常规肿瘤治疗患者生活质量的疗效(CAMONCO 2):一项随机对照试验的方案。
BMJ Open. 2022 Apr 25;12(4):e059960. doi: 10.1136/bmjopen-2021-059960.
9
Effects of Complementary and Alternative Medicine on Chemotherapy Delivery in Thai Patients.补充和替代医学对泰国患者化疗实施的影响。
Asian Pac J Cancer Prev. 2021 Dec 1;22(12):3977-3983. doi: 10.31557/APJCP.2021.22.12.3977.
10
Complementary and alternative medicine use in radiotherapy: what are patients using?补充和替代医学在放射治疗中的应用:患者在使用什么?
J Altern Complement Med. 2012 Nov;18(11):1014-20. doi: 10.1089/acm.2011.0334. Epub 2012 Aug 20.

引用本文的文献

1
Lessons Learned From Shared Decision-Making With Oral Anticoagulants: Viewpoint on Suggestions for the Development of Oral Chemotherapy Decision Aids.从口服抗凝药物的共同决策中吸取的经验教训:对口服化疗药物决策辅助工具开发建议的观点。
JMIR Cancer. 2024 Sep 11;10:e56935. doi: 10.2196/56935.
2
Decision aids for people facing health treatment or screening decisions.决策辅助工具用于帮助面临医疗保健治疗或筛查决策的人。
Cochrane Database Syst Rev. 2024 Jan 29;1(1):CD001431. doi: 10.1002/14651858.CD001431.pub6.
3
Formulation and Development of Bioadhesive Oral Films Containing (L.) F.H.Wigg Dry Ethanol Extract (F-UBE-HPC) with Antimicrobial and Anticancer Properties for Potential Use in Oral Cancer Complementary Therapy.

本文引用的文献

1
Complementary and alternative medicine among Singapore cancer patients.新加坡癌症患者中的补充和替代医学。
Ann Acad Med Singap. 2010 Feb;39(2):129-35.
含(L.)F.H.Wigg 干燥乙醇提取物(F-UBE-HPC)的具有抗菌和抗癌特性的生物粘附口腔膜的制剂与开发,用于口腔癌辅助治疗的潜在应用。
Pharmaceutics. 2022 Aug 28;14(9):1808. doi: 10.3390/pharmaceutics14091808.
4
Towards an open and effective dialogue on complementary medicine in oncology: protocol of patient participatory study 'COMMON'.迈向肿瘤学中补充医学的开放和有效对话:患者参与性研究“COMMON”的方案。
BMJ Open. 2021 Oct 20;11(10):e053005. doi: 10.1136/bmjopen-2021-053005.